Previous 10 | Next 10 |
Paragon 28 ( NYSE: FNA ) stock rose ~11% on Friday after Q3 revenue beat estimates and the company raised its FY22 outlook. Net loss widened to -$9.72M, compared to -$5.1M in Q3 2021. Q3 net revenue grew +28.33% Y/Y to $46M. U.S. quarterly revenue in...
Paragon 28 press release ( NYSE: FNA ): Q3 GAAP EPS of -$0.13 misses by $0.01 . Q3 revenue of $46M (+28.3% Y/Y) beats by $3.52M . Q3 revenue from U.S. was $40M, up 25% from last year. Q3 international net revenue surged more than 50% from a year ago to...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2022 and increased its 2022 net revenue guidance. Financial Hi...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 10, 2022. The compan...
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will be presenting at the Morgan Stanley 20th Annual Global Healthcare Conference. M...
Paragon 28, Inc. (FNA) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Matt Bacso - Gilmartin Group Albert DaCosta - Co Founder, President and Chief Executive Officer Stephen Deitsch - Chief Financial Officer Conference Cal...
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced two changes to the composition of its Board of Directors. Quentin Blackford has joined the Company’s Board of Directors and will serve t...
Paragon 28 press release ( NYSE: FNA ): Q2 GAAP EPS of -$0.13 (vs. -$0.05 Y/Y) misses by $0.06 . Revenue of $42.5M (+19.0% Y/Y) beats by $2.22M . FY22 net revenue guidance $176M (vs. consensus of $173.07M) Q3 net revenue guidance of $42.5M (vs. consensus of...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2022 and increased its 2022 revenue guidance. Financial Highlights ...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022. The companyȁ...
News, Short Squeeze, Breakout and More Instantly...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2024 after market close on Thursday, August 8, 2024. The Company’s managem...
2024-06-11 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-11 02:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...